Has Angioblast completed any pre-clinical validation of its technology on humans and animals and if so, what were the outcomes?
Angioblast’s MPC technology for bone regeneration has already been successfully tested with great success in animal studies. Pre-clinical animal studies using both rodents and sheep have demonstrated the ability of the MPCs to differentiate into a variety of tissue types, increase new blood vessel formation, induce the animal’s own ability to regenerate and significantly improve function in cardiovascular models.
